Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 14.04
-0.05 (-0.35%)
Oct 16, 2026, 3:00 PM CST
SHA:600535 Revenue
Tasly Pharmaceutical Group had revenue of 2.04B CNY in the quarter ending June 30, 2026, a decrease of -8.82%. This brings the company's revenue in the last twelve months to 8.15B, down -3.15% year-over-year. In the year 2025, Tasly Pharmaceutical Group had annual revenue of 8.24B, down -3.08%. That makes Tasly Pharmaceutical Group the 6,776th largest company in the world by revenue and 956th in China.
Revenue (ttm)
8.15B
Revenue Growth
-3.15%
P/S Ratio
2.57
Revenue / Employee
771.50K
Employees
10,563
Market Cap
20.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.24B | -261.66M | -3.08% |
| Dec 31, 2024 | 8.50B | -175.87M | -2.03% |
| Dec 31, 2023 | 8.67B | 36.58M | 0.42% |
| Dec 31, 2022 | 8.64B | 685.47M | 8.62% |
| Dec 31, 2021 | 7.95B | -5.62B | -41.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.